Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 25 of 382

TitleTypeExpected publication date
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidance
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]Technology appraisal guidance
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Technology appraisal guidance
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]Technology appraisal guidance
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]Technology appraisal guidance
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]Technology appraisal guidance
Voxelotor for treating sickle cell disease [ID1403]Technology appraisal guidance
Tirzepatide for managing overweight and obesity [ID6179]Technology appraisal guidance
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]Technology appraisal guidance
Surgical correction of hallux valgus using minimal access techniquesInterventional procedures guidance
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]Technology appraisal guidance
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Technology appraisal guidance
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]Technology appraisal guidance
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]Technology appraisal guidance
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Technology appraisal guidance
Endometriosis: diagnosis and management - diagnosing endometriosisNICE guideline

Results per page

  1. 10
  2. 25
  3. 50
  4. All